Age is no Barrier for Adults undergoing HCT for AML in CR1: Contemporary CIBMTR Analysis

Acute Myeloid Leukemia (AML) has a median age at diagnosis of 67 years. The most common curative therapy remains an allogeneic hematopoietic stem cell transplantation (HCT), yet it is complicated by treatment-related mortality (TRM) and ongoing morbidity including graft versus host disease (GVHD) th...

Descripción completa

Detalles Bibliográficos
Autores principales: Maakaron, Joseph E., Zhang, Mei-Jie, Chen, Karen, Abhyankar, Sunil, Bhatt, Vijaya Raj, Chhabra, Saurabh, Jurdi, Najla El, Farag, Sherif S., He, Fiona, Juckett, Mark, de Lima, Marcos, Majhail, Navneet, van der Poel, Marjolein, Saad, Ayman, Savani, Bipin, Ustun, Celalettin, Waller, Edmund K., Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Saber, Wael, Weisdorf, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232949/
https://www.ncbi.nlm.nih.gov/pubmed/35368040
http://dx.doi.org/10.1038/s41409-022-01650-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232949/
https://www.ncbi.nlm.nih.gov/pubmed/35368040
http://dx.doi.org/10.1038/s41409-022-01650-5

Ejemplares similares